Babkina A, Pisarev M, Grechko A, Golubev A
J Clin Med. 2024; 13(19).
PMID: 39408067
PMC: 11477565.
DOI: 10.3390/jcm13196007.
Kaplan A, Joseph K, Ghebrehiwet B
Front Allergy. 2022; 3:952753.
PMID: 35991308
PMC: 9382879.
DOI: 10.3389/falgy.2022.952753.
Arenas J, Szabo Z, van der Wal J, Maas C, Riaz T, Tonjum T
Virulence. 2021; 12(1):2902-2917.
PMID: 34903146
PMC: 8677018.
DOI: 10.1080/21505594.2021.2003115.
Wygrecka M, Birnhuber A, Seeliger B, Michalick L, Pak O, Schultz A
Blood Adv. 2021; 6(3):1074-1087.
PMID: 34861681
PMC: 8648369.
DOI: 10.1182/bloodadvances.2021004816.
Mohammed B, Matafonov A, Ivanov I, Sun M, Cheng Q, Dickeson S
Thromb Res. 2017; 161:94-105.
PMID: 29223926
PMC: 5776729.
DOI: 10.1016/j.thromres.2017.10.008.
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.
Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J
J Exp Med. 2009; 206(11):2381-95.
PMID: 19808248
PMC: 2768864.
DOI: 10.1084/jem.20091007.
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
Yang L, Sun M, Gailani D, Rezaie A
Biochemistry. 2009; 48(7):1517-24.
PMID: 19178150
PMC: 2654577.
DOI: 10.1021/bi802298r.
Bradykinin formation. Plasma and tissue pathways and cellular interactions.
Kaplan A, Joseph K, Shibayama Y, Nakazawa Y, Ghebrehiwet B, Reddigari S
Clin Rev Allergy Immunol. 1999; 16(4):403-29.
PMID: 9926288
DOI: 10.1007/BF02737659.
Binding of high-molecular-mass kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77.
Seaman F, Baglia F, Gurr J, Jameson B, Walsh P
Biochem J. 1994; 304 ( Pt 3):715-21.
PMID: 7818472
PMC: 1137393.
DOI: 10.1042/bj3040715.
Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
Scott C, Schapira M, James H, Cohen A, Colman R
J Clin Invest. 1982; 69(4):844-52.
PMID: 7076850
PMC: 370139.
DOI: 10.1172/jci110524.
Covalent structure of human haptoglobin: a serine protease homolog.
Kurosky A, Barnett D, Lee T, Touchstone B, Hay R, ARNOTT M
Proc Natl Acad Sci U S A. 1980; 77(6):3388-92.
PMID: 6997877
PMC: 349621.
DOI: 10.1073/pnas.77.6.3388.
Active site amino acid sequence of human factor D.
Davis 3rd A
Proc Natl Acad Sci U S A. 1980; 77(8):4938-42.
PMID: 6776531
PMC: 349964.
DOI: 10.1073/pnas.77.8.4938.
Cleavage and inactivation of Factor IX by granulocyte elastase.
Takaki A, Enfield D, Thompson A
J Clin Invest. 1983; 72(5):1706-15.
PMID: 6605369
PMC: 370459.
DOI: 10.1172/JCI111130.
Isolation and sequence characterization of a cDNA clone of human antithrombin III.
Chandra T, Stackhouse R, Kidd V, Woo S
Proc Natl Acad Sci U S A. 1983; 80(7):1845-8.
PMID: 6572945
PMC: 393706.
DOI: 10.1073/pnas.80.7.1845.
Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse. Role of the endothelium and plasma proteinase inhibitors.
Fuchs H, Pizzo S
J Clin Invest. 1983; 72(6):2041-9.
PMID: 6196377
PMC: 437045.
DOI: 10.1172/JCI111169.
Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
Usharani P, Warn-Cramer B, Kasper C, Bajaj S
J Clin Invest. 1985; 75(1):76-83.
PMID: 3965513
PMC: 423405.
DOI: 10.1172/JCI111700.
Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor.
Walsh P, Sinha D, Kueppers F, Seaman F, Blankstein K
J Clin Invest. 1987; 80(6):1578-86.
PMID: 3500185
PMC: 442426.
DOI: 10.1172/JCI113244.
Intrinsic versus extrinsic coagulation. Kinetic considerations.
Warn-Cramer B, Bajaj S
Biochem J. 1986; 239(3):757-62.
PMID: 3493767
PMC: 1147351.
DOI: 10.1042/bj2390757.
Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.
Akiyama H, Sinha D, Seaman F, Kirby E, Walsh P
J Clin Invest. 1986; 78(6):1631-7.
PMID: 3491093
PMC: 423936.
DOI: 10.1172/JCI112756.
Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
Scott C, Carrell R, Glaser C, Kueppers F, Lewis J, Colman R
J Clin Invest. 1986; 77(2):631-4.
PMID: 3484755
PMC: 423401.
DOI: 10.1172/JCI112346.
